3rd Quarter - Report

AKIN GUMP STRAUSS HAUER & FELD for BIOSPLICE THERAPEUTICS, INC.

Period 3rd Quarter 2026 Filed Oct 20, 2026 Signed by Brian Pomper

Official filing
Firm
AKIN GUMP STRAUSS HAUER & FELD
Client
BIOSPLICE THERAPEUTICS, INC.
Income
$110,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the development of therapies for osteoarthritis and areas of significant unmet medical need; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R. 9260).

LobbyistCovered position, as disclosed
ANNA ABRAM —
MOLLY BRIMMER-LOLLI —
KANDIS MCCLURE —

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Executive Office of the President (EOP); Food & Drug Administration (FDA); SENATE

Bills named: H.R. 9260 (119th), H.R. 8646 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.